DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth
MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets
DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/
From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International
The collaboration will leverage DBS’ digital banking capabilities and Ant International’s cutting-edge financial technologies such as AI and blockchain, to scale cross-border payments, strengthen connectivity and drive innovations in the financial ecosystem.
The Memorandum of Understanding (MoU) was inked on the sidelines of the Singapore Fintech Festival 2025, committing DBS and Ant International’s key businesses – Alipay+, Antom, WorldFirst and Bettr Platform Tech – to a comprehensive partnership spanning several areas of strategic cooperation. These areas of collaboration include:
- Boosting cross-border payments connectivity: DBS PayLah! will join the Alipay+ payments ecosystem, enabling over three million DBS PayLah! users to make QR codes payments to more than 150 million merchants in over 100 markets.
- Exploring near-instant remittances to 1.8 billion consumer accounts on Alipay+: Ant International and DBS are currently exploring a bank-to-wallet solution that enables real-time remittances between DBS customers and more than 1.8 billion user accounts on the Alipay+ ecosystem. The solution will use ISO 20022 messaging standards and leverage the SWIFT network. Both organisations are also exploring further innovative solutions to enhance and simplify remittances between DBS customers and Alipay+ ecosystem users.
- Supporting small and medium enterprises (SMEs) on their digital transformation journey: DBS will partner with Antom, Ant International’s unified merchant payment and digitisation services provider, to explore potential solutions that can meaningfully support SMEs in advancing their digital transformation journey. An example being considered includes the Model Context Protocol (MCP)-based Antom Agentic Payment solution, which integrates Antom’s unique Alternative Payment Method checkout capabilities, industry-leading payment mandate model, and trusted AI technologies. DBS will also work with WorldFirst to scale up same-day and near-instant cross-border payments solutions for SME clients.
- Fostering innovation in regional fintech ecosystems: DBS and Ant International further reiterated their shared commitment to driving innovation in the financial sector, by deepening their existing collaboration on tokenised deposits1.
Peng Yang, CEO of Ant International, said: “We are proud to deepen our partnership with DBS, whom we have already been working closely with since 2013, on various initiatives including SME payment solutions and most recently, tokenised deposits. With a shared vision on enhancing inclusive growth for local and regional commerce, as well as nurturing local innovation and talent, we look forward to bringing our know-how in payments and digitalisation together to create even stronger synergy to continuously boost the digital economy in this region. Together, we’ll make a difference to the region by driving inclusive and sustainable growth.”
Tan Su Shan, CEO of DBS, said: “DBS is pleased to have the privilege to expand our partnership with Ant International. They are a truly like-minded partner in purpose-driven innovation, having demonstrated a shared vision for leveraging cutting-edge technology to create more efficient and inclusive financial ecosystems. By synergising our strengths, we can unlock new avenues for growth, accelerate future-ready solutions like tokenised deposits and agentic payments – and reimagine the future of finance to drive greater impact for our clients and customers.”
About DBS
DBS is a leading financial services group in Asia with a presence in 19 markets. Headquartered and listed in Singapore, DBS is in the three key Asian axes of growth: Greater China, Southeast Asia and South Asia. The bank's "AA-" and "Aa1" credit ratings are among the highest in the world.
Recognised for its global leadership, DBS has been named “World’s Best Bank” by Global Finance, “World’s Best Bank” by Euromoney and “Global Bank of the Year” by The Banker. The bank is at the forefront of leveraging digital technology to shape the future of banking, having been named “World’s Best Digital Bank” by Euromoney and the world’s “Most Innovative in Digital Banking” by The Banker. In addition, DBS has been accorded the “Safest Bank in Asia“ award by Global Finance for 17 consecutive years from 2009 to 2025.
DBS provides a full range of services in consumer, SME and corporate banking. As a bank born and bred in Asia, DBS understands the intricacies of doing business in the region’s most dynamic markets.
DBS is committed to building lasting relationships with customers, as it banks the Asian way. Through the DBS Foundation, the bank creates impact beyond banking by uplifting lives and livelihoods of those in need. It provides essential needs to the underprivileged, and fosters inclusion by equipping the underserved with financial and digital literacy skills. It also nurtures innovative social enterprises that create positive impact.
With its extensive network of operations in Asia and emphasis on engaging and empowering its staff, DBS presents exciting career opportunities. For more information, please visit www.dbs.com.
About Ant International
With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, Ant International’s unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112714266/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines13.11.2025 07:00:00 CET | Press release
Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix’s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing will be used to: Advance the ongoing Phase I clinical trial of V-212, with topline results expected in Q1 2026. Prepare for a planned Phase Ib combination trial evaluating V-212 with an approved pneumococcal conjugate vaccine (PCV). Complete OPK assay validation to support immunogenicity and functional data read-outs. Implement platform enhancements to the company’s proprietary Synthetic Virus-Like Particle (SVLP) technology. Progress next-generation serotype-independent pneumococcal vaccine programs toward preclinical development. “This financing demonstrates the continued confidence and co
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 05:00:00 CET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release
Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom